Furthermore, osimertinib has improved CNS activity over first- and second-generation EGFR TKIs and chemotherapies in patients with previously treated EGFR T790M-positive NSCLC and treatment-naïve EGFR-sensitizing mutation-positive NSCLC in phase III prospective trials [6,7]. Here, EGFR is linked to non-small cell lung carcinoma.